Venture Partner at Samsara BioCapital
View Live Interactive Profile →Keith M. Gottesdiener, M.D. is a Venture Partner at Samsara BioCapital. The firm's team page states he has held leadership roles spanning academia, pharmaceutical R&D and public biotechnology companies. He most recently served as President and Chief Executive Officer of Prime Medicine, Inc., leading the gene-editing company through its IPO, and before that as Chief Executive Officer of Rhythm Pharmaceuticals, Inc., where he oversaw the development and approval of setmelanotide for three indications in rare genetic forms of obesity. Before joining the biotechnology industry he spent 16 years at Merck Research Laboratories as Worldwide Head of Late-Stage Development and Worldwide Head of Early Development. Earlier he was Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. He received his M.D. from the University of Pennsylvania Medical School and his A.B. in Applied Mathematics from Harvard University. Samsara's team page does not state the year he joined the firm.